Pharmaceutical manufacturing operates at a quality standard most industries never have to think about.
A contaminated batch in automotive means a rework. In pharma it means a recall, a regulatory action, and in sterile manufacturing, a potential patient safety event.
The contamination problems we see across pharma facilities are remarkably consistent. The same failure modes appear across API manufacturing, formulation lines, sterile fill-finish and medical device production regardless of facility size or equipment quality.
Here are the four most common ones and what a properly engineered cleaning process looks like for each.
1. BIOFILM IN PROCESS EQUIPMENT
Biofilm forms when microorganisms attach to a surface and produce a protective matrix that makes them resistant to standard cleaning agents. A biofilm-contaminated vessel or pipe can seed finished product with microbial contamination even after what appears to be a thorough clean-in-place cycle.
The conditions that allow it to establish are common. Residual nutrients on product contact surfaces. Water systems not maintained at correct temperature or flow velocity. Dead legs in pipework where fluid sits stagnant.
The fix is not a stronger disinfectant. Biofilm’s protective matrix makes it highly tolerant of chemical agents. The fix is a cleaning process engineered to physically disrupt the biofilm before chemical disinfection.
Ultrasonic cleaning is particularly effective here. Cavitation energy penetrates surface irregularities and internal geometries that spray or immersion cleaning cannot reliably reach.
2. CROSS-CONTAMINATION BETWEEN PRODUCT CAMPAIGNS
In multi-product facilities, equipment is shared across different product campaigns. The requirement is clear: residues from the previous product must be reduced to a level that cannot affect the next product or patient.
What we see repeatedly is facilities running cleaning processes validated years ago against a product portfolio that no longer reflects current production. New products have been introduced. Equipment has been modified. Batch sizes have changed. But the cleaning validation data in the quality system has not kept up.
The solution requires two things. A cleaning validation programme treated as a living document rather than a one-time exercise. And cleaning equipment capable of delivering consistent, reproducible results so that validation data actually means something cycle after cycle.
3. ENDOTOXIN CONTAMINATION IN STERILE MANUFACTURING
Endotoxins are fragments of gram-negative bacterial cell walls. They survive standard sterilisation processes that kill the organisms themselves. In injectable products, endotoxin contamination causes fever, inflammation and in severe cases septic shock.
The most common source is water. Purified water and water for injection systems that are not properly maintained allow bacteria to establish and shed endotoxins into everything downstream.
The second source is inadequate depyrogenation of product contact components. Standard autoclave sterilisation is not sufficient for endotoxin removal. Depyrogenation requires dry heat at 250 degrees Celsius for a minimum of 30 minutes.
This distinction is routinely missed in facilities that treat sterility and pyrogenicity as the same problem with the same solution. They are not.
4. PARTICULATE CONTAMINATION IN INJECTABLE PRODUCTS
Visible and sub-visible particulate in injectable products is one of the leading causes of batch rejection globally. Sources include glass delamination from vials, rubber particles from stopper processing, metal particles from filling equipment wear and fibre from operator garments.
Particulate can be introduced at any stage and is often not detectable until 100% inspection of filled units. By that point the batch value at risk is significant.
Cleaning of components before they enter the fill-finish environment is one of the most critical control points. Water quality, filtration integrity, rinse water bioburden, drying air filtration and component handling between cleaning and use all need to be controlled.
A component cleaned to a high standard and then handled incorrectly is not a clean component.
THE COMMON ROOT CAUSE
These four problems look different on the surface. But they share the same root cause.
Cleaning processes that were not engineered for the specific contamination challenge they are being asked to solve.
A properly engineered pharmaceutical cleaning process starts with understanding what needs to come off. The contamination profile, the surface geometry, the downstream application and the regulatory standard it needs to meet. The equipment, the chemistry, the parameters and the validation protocol are all built around that understanding.
At Ralsonics, that is where every client engagement starts. Not with equipment selection but with the contamination problem.
If you are seeing any of the failure modes described above in your facility, or preparing for a regulatory audit and want to benchmark your current cleaning process, contact Ralsonics for a consultation.
